{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:19:36Z","timestamp":1790482776227,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.leukres.2023.107407","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:43:22Z","timestamp":1698788602000},"page":"107407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Venetoclax-based therapy in treatment-na\u00efve and relapsed\/refractory acute myeloid leukemia"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9545-8769","authenticated-orcid":false,"given":"Aditya","family":"Ravindra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1311-6227","authenticated-orcid":false,"given":"Grerk","family":"Sutamtewagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-1510","authenticated-orcid":false,"given":"Prajwal","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.leukres.2023.107407_bib1","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.leukres.2023.107407_bib2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107407_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PPO.0000000000000567","article-title":"How we incorporate venetoclax in treatment regimens for acute myeloid leukemia","volume":"28","author":"Maiti","year":"2022","journal-title":"Cancer J."},{"key":"10.1016\/j.leukres.2023.107407_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720986646","article-title":"Venetoclax-containing regimens in acute myeloid leukemia","author":"Aldoss","year":"2021","journal-title":"Ther. Adv. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107407_bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2023.107407_bib6","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.leukres.2023.107407_bib7","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2023.107407_bib8","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2023.107407_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-019-0133-1","article-title":"Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose","volume":"8","author":"Jilg","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2023.107407_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2023.107407_bib11","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1080\/10428194.2022.2042688","article-title":"Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia","volume":"63","author":"Graveno","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2023.107407_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-022-01229-z","article-title":"Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure","volume":"15","author":"Short","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2023.107407_bib13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2023.107407_bib14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2023.107407_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers14010022","article-title":"Venetoclax in relapsed\/refractory acute myeloid leukemia: are supporting evidences enough?","volume":"14","author":"Brancati","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.leukres.2023.107407_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107407_bib17","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.leukres.2023.107407_bib18","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1080\/10428194.2021.1966788","article-title":"Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant","volume":"62","author":"Bewersdorf","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.leukres.2023.107407_bib19","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2023.107407_bib20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/ajh.25859","article-title":"The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia","volume":"95","author":"Byrne","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107407_bib21","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","article-title":"Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML","volume":"7","author":"Issa","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107407_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25929","article-title":"Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia","author":"Aldoss","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2023.107407_bib23","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107407_bib24","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/jcm10081684","article-title":"Venetoclax-based regimens for relapsed\/refractory acute myeloid leukemia in a real-life setting: a retrospective single-center experience","volume":"10","author":"Piccini","year":"2021","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.leukres.2023.107407_bib25","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","author":"Bewersdorf","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2023.107407_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.2022015832","article-title":"Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:02Z","timestamp":1758935042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":26,"alternative-id":["S0145212623006720"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107407","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax-based therapy in treatment-na\u00efve and relapsed\/refractory acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107407"}}